EC1169: Phase I data

Data from 7 evaluable patients with recurrent mCRPC in an open-label, U.S. Phase I trial showed that once-weekly 0.3, 0.45 and 0.6 mg/m 2 and thrice-weekly 0.2, 0.3, 0.45 and 0.6 mg/m 2 doses of IV EC...